(Q33770608)

29 July 2017

1 reference

title

Coating-techniques to improve the hemocompatibility of artificial devices used for extracorporeal circulation (English)

1 reference

29 July 2017

Wendel HP

1

1 reference

29 July 2017

Ziemer G

series ordinal

2

1 reference

29 July 2017

publication date

1 September 1999

1 reference

European Journal of Cardio-Thoracic Surgery

29 July 2017

published in

1 reference

29 July 2017

volume

16

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

342-350

1 reference

Aprotinin complements heparin bonding in an in vitro model of cardiopulmonary bypass

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Heparin coating with aprotinin reduces blood activation during coronary artery operations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

HEPARIN BONDING ON COLLOIDAL GRAPHITE SURFACES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Heparin-coated cardiopulmonary bypass circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Extracorporeal circulation, hemocompatibility, and biomaterials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Biocompatibility in cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Heparin-coated cardiopulmonary bypass circuits and 25% reduction of heparin dose in coronary artery surgery--a clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Experimental studies on three types of heparin-coated cardiopulmonary bypass circuits

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

A clinical study for the durability of oxygenators on cardiopulmonary support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Specific complement inhibition with heparin-coated extracorporeal circuits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

The search for thromboresistance using immobilized heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Membrane asymmetry and blood coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Perioperative course and recovery after heparin-coated cardiopulmonary bypass: low-dose versus high-dose heparin management

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

Heparin-coated circuit in coronary surgery. A clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

SIRS--the systemic inflammatory response syndrome after cardiac operations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Hemostatic complications of cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin-coated equipment reduces the risk of oxygenator failure

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Risk and benefit of low systemic heparinization during open heart operations

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Cardiopulmonary bypass with heparin-coated circuits and reduced systemic anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Enhanced blood conservation in primary coronary artery bypass surgery using heparin-bonded circuits with lower anticoagulation

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Effects on Coagulation and Fibrinolysis With Reduced Versus Full Systemic Heparinization and Heparin-Coated Cardiopulmonary Bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Biocompatibility of heparin-coated circuits used in cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

High and low heparin dose with heparin-coated cardiopulmonary bypass: activation of complement and granulocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Effect of anticoagulation protocol on outcome in patients undergoing CABG with heparin-bonded cardiopulmonary bypass circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin-bonded circuits with a reduced anticoagulation protocol in primary CABG: a prospective, randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Decreased blood loss after cardiopulmonary bypass using heparin-coated circuit and 50% reduction of heparin dose

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Low heparinization with heparin-bonded bypass circuits: is it a safe strategy?

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin-bonded circuits: clinical outcomes and costs

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Reduced complement activation and improved postoperative performance after cardiopulmonary bypass with heparin-coated circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Centrifugal pump and heparin coating improves cardiopulmonary bypass biocompatibility

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

The effects of Carmeda Bioactive Surface on human blood components during simulated extracorporeal circulation

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Complete heparin-coated cardiopulmonary bypass and low heparin dose reduce complement and granulocyte activation

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Complement and granulocyte activation in two different types of heparinized extracorporeal circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Effects of heparin coating of cardiopulmonary bypass circuits on in vitro oxygen free radical production during coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Endothelin-1 and neutrophil activation during heparin-coated cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin-coated cardiopulmonary bypass circuits in coronary bypass surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Beneficial effects of Duraflo II heparin-coated circuits on postperfusion lung dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Biocompatible surfaces using methacryloylphosphorylcholine laurylmethacrylate copolymer

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Complications of extracorporeal life support systems using heparin-bound surfaces. The risk of intracardiac clot formation

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

The use of a heparin removal device: a valid alternative to protamine.

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Does heparin coating improve biocompatibility? A study on complement, blood cells and postoperative morbidity during cardiac surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Biocompatibility reflected by haemostasis variables during cardiopulmonary bypass using heparin-coated circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Circulating cytokines and granulocyte-derived enzymes during complex heart surgery. A clinical study with special reference to heparin-coating of cardiopulmonary bypass circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin bonding of bypass circuits reduces cytokine release during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Complete heparin-coated (CBAS) cardiopulmonary bypass and reduced systemic heparin dose; effects on coagulation and fibrinolysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Thrombin generation during cardiopulmonary bypass using heparin-coated or standard circuits

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin-coated circuits reduce the formation of TNF alpha during cardiopulmonary bypass

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Duraflo II coating of cardiopulmonary bypass circuits reduces complement activation, but does not affect the release of granulocyte enzymes : a European multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Monocyte tissue factor expression, cell activation, and thrombin formation during cardiopulmonary bypass: a clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Complement consumption during cardiopulmonary bypass: comparison of Duraflo II heparin-coated and uncoated circuits in fully heparinized patients

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Heparin coating of extracorporeal circuits inhibits contact activation during cardiac operations

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Induction of monocyte tissue factor procoagulant activity during coronary artery bypass surgery is reduced with heparin-coated extracorporeal circuit

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Biocompatibility of heparin-coated extracorporeal bypass circuits: a randomized, masked clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

Completely heparinized cardiopulmonary bypass and reduced systemic heparin: Clinical and hemostatic effects

1 reference

https://api.crossref.org/works/10.1016%2FS1010-7940%2899%2900210-9

7 January 2021

10.1016/S1010-7940(99)00210-9

Identifiers

DOI

1 reference

29 July 2017

1 reference